Using multigene tests to select treatment for early-stage breast cancer.

Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76

WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials (2013) 1.03

Closing the gap between knowledge and clinical application: challenges for genomic translation. PLoS Genet (2015) 0.94

Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res (2015) 0.93

The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts. Cancer Epidemiol Biomarkers Prev (2014) 0.84

SNP 1772 C > T of HIF-1α gene associates with breast cancer risk in a Taiwanese population. Cancer Cell Int (2014) 0.78

Spontaneous genomic alterations in a chimeric model of colorectal cancer enable metastasis and guide effective combinatorial therapy. PLoS One (2014) 0.77

SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer. EBioMedicine (2016) 0.75

RAS pathway biomarkers for breast cancer prognosis. Clin Lab Int (2016) 0.75

Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03

Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09

Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85

Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure (2008) 2.79

Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature (2007) 2.78

DGIdb: mining the druggable genome. Nat Methods (2013) 2.26

Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. J Biol Chem (2009) 1.36

Exome sequencing and cis-regulatory mapping identify mutations in MAK, a gene encoding a regulator of ciliary length, as a cause of retinitis pigmentosa. Am J Hum Genet (2011) 1.16

Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers. Mol Cell Proteomics (2012) 1.10

Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinase. Mol Cell Proteomics (2011) 0.91

Identification of targets of c-Src tyrosine kinase by chemical complementation and phosphoproteomics. Mol Cell Proteomics (2012) 0.90

Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data. PLoS One (2013) 0.86

Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. J Biol Chem (2013) 0.85

Incorporating genomics into breast cancer clinical trials and care. Clin Cancer Res (2013) 0.85

Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer. Electrophoresis (2014) 0.78